Joseph Martel
Ophthalmology · Pittsburgh, PANPI 1326247545
Payments from drug & device makers
Across 47 payments — averaging $179.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Argenx US, Inc.$2K
- Biogen$1K
- Topcon Healthcare, Inc.$517
- Spark Therapeutics, Inc.$120
- Carl Zeiss Meditec, Inc.$70
- plus $86 from 2 others
What the payments were for
- Travel & lodging$1,85667%
- Food & beverage$91533%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 26 | $4,439 |
| Argenx US, Inc. | 11 | $1,977 |
| Biogen | 1 | $1,240 |
| Topcon Healthcare, Inc. | 1 | $517 |
| Spark Therapeutics, Inc. | 4 | $120 |
| Carl Zeiss Meditec, Inc. | 1 | $70 |
| Alcon | 2 | $65 |
| Astellas Pharma US Inc | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYVGART$1,523
How this compares
$8,449 in reported general payments places this provider in the 80th percentile of 920 ophthalmology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 12 | $7,960 |
| Difluprednate | 22 | $6,106 |
| Prednisolone Acetate | 60 | $3,163 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 65 | $1,298 |
| Brimonidine Tartrate | 45 | $669 |
| Latanoprost | 54 | $385 |
| Dorzolamide Hcl | 17 | $279 |
| MoxifloxacinMoxifloxacin Hcl | 15 | $265 |
| Ketorolac Tromethamine | 17 | $192 |
| ErythromycinErythromycin Base | 16 | $181 |
| Timolol Maleate | 14 | $94 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis | $4,439 | $7,96012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 920 ophthalmology providers in Pennsylvania.
Other ophthalmology in Pittsburgh
- Francis MahPittsburgh$1.2M
- Robert NoeckerPittsburgh$634K
- Srinivas KondapalliPittsburgh$215K
- Deepinder DhaliwalPittsburgh$170K
- Deval ParanjpePittsburgh$121K
- Ian ConnerPittsburgh$103K
- Vishal JhanjiPittsburgh$80K
- David AlmeidaErie$6.3M
- William ChristieCranberry Township$5.2M
- Carl RegilloPlymouth Meeting$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.